Contact the ACC Registration and Housing Center

  • (888) 322-2878
    (toll-free)
  • (847) 996-5822 (International)
  • M-F, 9:00 a.m. - 6:00 p.m. ET
  • acc@experient-inc.com
  • Industry-Expert Theaters
    Expo Hall, #23077 and #23031

    Connect with the experts in the Industry-Expert Theaters as presenters share the latest in cardiovascular practices, services and technologies while you enjoy refreshments or lunch — presentations are conveniently scheduled during the daily breaks.

      Saturday, March 28
      Saturday, March 28

    10:15 a.m. – 11:15 a.m.

    Empowering the Treatment of Heart Failure and Structural Heart Disease
    Theater 1, Expo Hall, #23077
    Sponsored by Abbott

    Heart disease continues to be the leading cause of death in the U.S. with heart failure mortality rate increasing 24% in recent years. It has become increasingly important to recognize when medications alone are not enough and referral to device interventions may be required. In this program, cardiology experts will discuss the latest device advancements and clinical data for MitraClip™ Transcatheter Mitral Valve Repair, Amplatzer™ Patent Foramen Ovale (PFO) Occluder, CardioMEMS™ HF System, and HeartMate 3™ LVAD therapy.

    • Clinical Challenges in Managing Heart Disease
    • MitraClip™ Therapy and Amplatzer™ PFO Occluder – Identifying and Treating Structural Heart Diseases
    • CardioMEMS™ HF System – Proven, Proactive, Personalized
    • HeartMate 3™ LVAD Destination Therapy – Real World Evidence Looking Beyond Bridge to Transplantation

    Amgen: Cardiovascular Patient Cases
    Theater 2, Expo Hall, #23031
    Sponsored by Amgen

    Speaker:
    Seth J. Baum, MD, FACC, FACPM, FAHA, FNLA

    12:45 p.m. – 1:45 p.m.

    Title to be Announced

    TBA Theater 1, Expo Hall, #23077
    Sponsored by Novartis Pharmaceuticals Corporation

    Sponsored by Novartis Pharmaceuticals Corporation, and the faculty will be compensated for their time.

    Thinking Beyond HFpEF: The Dizzying Universe of hATTR Amyloidosis
    Theater 2, Expo Hall, #23031
    Sponsored by Alnylam Pharmaceuticals

    12:45 p.m.
    Welcome and Introduction
    Dr. Jose Nativi‐Nicolau, Salt Lake City, USA

    12:50 p.m.
    Beyond the Heart: Autonomic Dysfunction in hATTR Amyloidosis
    Dr. Amanda Peltier, Nashville, USA

    1:05 p.m.
    Looking Back at hATTR Amyloidosis Red Flags
    Dr. Nitasha Sarswat, Chicago, USA

    1:20 p.m.
    Inside the Viewing Room: Diagnosis of hATTR Amyloidosis Through Cardiac Imaging
    Dr. Prem Soman, Pittsburgh, USA

    1:40 p.m.
    Q&A
    Dr. Jose Nativi‐Nicolau, Salt Lake City, USA

    3:45 p.m. – 4:45 p.m.

    VASCEPA® (icosapent ethyl): Elevating the Standard of Care
    Theater 1, Expo Hall, #23077
    Sponsored by Amarin Pharma, Inc

    Speaker:
    Alan S. Brown MD, FACC, FAHA, FNLA, FASPC
    Director, Division of Cardiology & Director of the Lipid Clinic Advocate Lutheran General Hospital

    Jardiance® (empagliflozin) Tablets: Data From the Comprehensive Clinical Development Program
    Theater 2, Expo Hall, #23031
    Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA

      Sunday, March 29
      Sunday, March 29

    9:45 a.m. – 10:45 a.m.

    Title to be Announced
    Theater 1, Expo Hall, #23077
    Sponsored by Novartis Pharmaceuticals Corporation

    Title to be Announced
    Theater 2, Expo Hall, #23031
    Sponsored by Amgen

    Speaker:
    Nihar R. Desai, MD, MPH

    12:45 p.m. – 1:45 p.m.

    TEGSEDI®: Targeting the Source of Polyneuropathy From Hereditary ATTR Amyloidosis
    Theater 1, Expo Hall, #23077
    Sponsored by Akcea Therapeutics

    An innovative patient-moderated panel, including a Cardiologist and a Neurologist with discussion on how early diagnosis and treatment are imperative in managing hATTR amyloidosis with polyneuropathy. In addition these experts share various perspectives on a unique treatment option and its effects on progression of neuropathy and patient quality of life.

    Amgen: Cardiovascular Patient Cases
    Theater 2, Expo Hall, #23031
    Sponsored by Amgen

    Speaker:
    Alan S. Brown, MD, FACC, FAHA, FNLA

    3:45 p.m. – 4:45 p.m.

    Heart Failure With Preserved Ejection Fraction: Current Perspectives and Opportunities to Optimize Care Surrounding Hospitalization
    Theater 1, Expo Hall, #23077
    Sponsored by Novartis Pharmaceuticals Corporation

    Heart failure with preserved ejection fraction (HFpEF) accounts for approximately 50% of heart failure cases, and the prevalence of HFpEF is increasing at a rate of 1% per year. HFpEF management is complicated by diverse clinical phenotypes, complex pathophysiology, and a clinical course that often includes hospitalization. Hospitalizations are associated with increased risk of mortality and rehospitalization in patients with HFpEF. Therefore, early recognition of worsening symptoms that often precipitate hospitalization is critical. This program will review current perspectives on HFpEF, including disease burden, clinical manifestations, and underlying pathophysiology, and describe opportunities for optimizing care surrounding hospitalization and worsening HFpEF.

    Sponsored by Novartis Pharmaceuticals Corporation, and the faculty will be compensated for their time.

    Speaker:
    Sanjiv Shah, MD, FAHA, FACC, FASE
    Stone Professor of Medicine, Director of Research, Bluhm Cardiovascular Institute, Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine

    Title to be Announced
    Theater 2, Expo Hall, #23031
    Sponsored by Amgen

    Speakers:
    Manos S. Brilakis, MD, PhD

    Payal Kohli, MD, FACC

      Monday, March 30
      Monday, March 30

    9:45 a.m. – 10:45 a.m.

    Managing LV Dysfunction and SCD Risk — Optimizing Medical Therapy for HF Patients
    Theater 1, Expo Hall, #23077
    Sponsored by ZOLL

    Confronting CVD in Patients With T2D: A Review of the Pathophysiologic Links and Management Strategies
    Theater 2, Expo Hall, #23031
    Sponsored by Novo Nordisk

    This program reviews the links between cardiovascular disease and T2D and how current guidelines have made this a critical feature of how patients are managed. Details regarding their pathophysiologic links are discussed using a series of infographics which show how inflammation and endothelial dysfunction play key roles in the development of CVD and how T2D amplifies this process. Lastly, the significance of CVOTs and their impact on the updated ADA and ACC guidelines are also discussed.

    Speaker
    Joshua M. Stolker, MD
    STEMI Director, Mercy Heart and Vascular, Washington, Missouri; Adjunct Associate Professor, Saint Louis University, St. Louis, Missouri

    11:30 a.m. – 12:30 p.m.

    A New Approach for Managing Lipids: A Novel, Non-Statin, Oral Therapy for Lowering LDL-C
    Theater 1, Expo Hall, #23077
    Sponsored by Esperion

    The session will cover the following information:

    • Cardiovascular disease and increasing death rates
    • Unique mechanism of action of bempedoic acid
    • Pooled efficacy data for bempedoic acid
    • Pooled safety data for bempedoic acid
    • Overview slide of the CLEAR Outcomes trial

    Speaker:
    Pam R. Taub, MD, FACC, FASPC
    Director of Step Family Foundation Cardiovascular, Rehabilitation and Wellness Center, Associate Professor of Medicine, UC San Diego Health System, Division of Cardiovascular Medicine, La Jolla, California

    Title to be Announced
    Theater 2, Expo Hall, #23031
    Sponsor to be announced


    Schedule is current as of Jan. 17, 2020, and is subject to change. Please check back for updates.

    *Industry-Expert Theater presentations are not part of ACC.20/WCC, as planned by its Program Committee, and do not qualify for continuing medical education (CME), continuing nursing education (CNE) or continuing education (CE) credit.

    ADVERTISEMENT
    ACC Logo
    ACC.20/WCC on Social Media:
          
    2019 American College of Cardiology Foundation. Visit ACC.org
    Terms and Conditions Registered User Agreement Advertising and Sponsorship Policy Privacy Policy Cookie Policy Contact Us